Review for 10.1186/s12876-020-01474-x (2020)

Reviewer’ s report
Title: Crohn's disease exacerbated by IL-17 inhibitors in patients with psoriasis:A Case Report
Version: 0Date: 04 Apr 2020
Reviewer: Zhong Guang Luo
Reviewer's report:
The author found that this case had a history of psoriasis and suspected Crohn's disease. During
treatment with IL-17 inhibitors, Crohn's disease worsens. After using targeted IL-23 treatment,Crohn's disease alleviated.Although the serum levels of IL-17 / IL-23 have been reported to increase in patients with Crohn'sdisease, and targeting IL-23 has achieved positive results, several studies targeting IL-17 have notachieved a definite effect.Two questions1. Does this patient have an elevated serum IL-17 level before using the IL-17 inhibitor, and is ittested again after use? After using targeted IL-23 treatment, do you test the serum IL-17 after thesymptoms have been alleviated?2. The expression of IL-17A should be detected by immunohistochemistry in intestinal biopsysamples from different colonscopy?
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Unable to assessAre the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
YesAre you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?If an additional statistical review is recommended, please specify what aspects require furtherassessment in your comments to the editors.
Not relevant to this manuscript
Quality of written English
Please indicate the quality of language in the manuscript:
AcceptableDeclaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
I declare that I have no competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named reportincluding any attachments I upload will be posted on the website along with the authors'responses. I agree for my report to be made available under an Open Access Creative CommonsCC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any commentswhich I do not wish to be included in my named report can be included as confidential commentsto the editors, which will not be published.
I agree to the open peer review policy of the journal